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ABSTRACT
Malignant mesothelioma is a deadly tumor whose diagnosis and treatment 
remain very challenging. There is an urgent need to advance our understanding 
of mesothelioma biology and to identify new molecular markers for improving 
management of patients. CD157 is a membrane glycoprotein linked to ovarian cancer 
progression and mesenchymal differentiation. The common embryonic origin of 
ovarian epithelial cells and mesothelial cells and the evident similarities between 
ovarian and mesothelial cancer prompted us to investigate the biological role and 
clinical significance of CD157 in malignant pleural mesothelioma (MPM).
CD157 mRNA and protein were detected in four of nine MPM cell lines of diverse 
histotype and in 85.2% of MPM surgical tissue samples (32/37 epithelioid; 37/44 
biphasic). CD157 expression correlated with clinical aggressiveness in biphasic MPM. 
Indeed, high CD157 was a negative prognostic factor and an independent predictor 
of poor survival for patients with biphasic MPM by multivariate survival analysis 
(HR = 2.433, 95% CI 1.120-5.284; p = 0.025). In mesothelioma cell lines, CD157 
gain (in CD157-negative cells) or knockdown (in CD157-positive cells) affected cell 
growth, migration, invasion and tumorigenicity, most notably in biphasic MPM cell 
lines. In these cells, CD157 expression was associated with increased activation of 
the mTOR signaling pathway, resulting in decreased platinum sensitivity. Moreover, a 
trend towards reduced survival was observed in patients with biphasic MPM receiving 
postoperative platinum-based chemotherapy. These findings indicate that CD157 is 
implicated in multiple aspects of MPM progression and suggest that CD157 expression 
could be used to stratify patients into different prognostic groups or to select patients 
that might benefit from particular chemotherapeutic approach.
INTRODUCTION
Malignant mesothelioma is a rare but highly 
aggressive tumor arising from the mesothelial cells lining 
the pleural, peritoneal and pericardial cavities. Exposure 
to asbestos is the major risk factor [1] although a latency 
period often exceeding four decades may pass from first 
exposure to disease onset [2]. Consequently, the incidence 
of mesothelioma is rising and will continue to rise in the 
coming decades as a result of past widespread exposure 
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to asbestos [3]. Malignant pleural mesothelioma (MPM) 
is by far the most common form of this disease, and a 
vast majority of patients are diagnosed in advanced 
stages. By histopathology, MPM mainly consists of three 
distinct subtypes: epithelioid, sarcomatoid and biphasic. 
The epithelioid subtype is the most common, accounting 
for 50-60% of MPM: it is characterized by a papillary 
or pseudo-glandular growth pattern and has the best 
prognosis. The sarcomatoid subtype is the rarest form: it 
is characterized by a diffuse sarcomatous morphology and 
has the worst prognosis. The biphasic subtype accounts for 
20-35% of MPM: these tumors contain both epithelial and 
mesenchymal components that merge into one another, 
likely representing an intermediate differentiation step in 
the epithelial-to-mesenchymal transition (EMT) process 
[4, 5]. 
Treatment of MPM is hampered by the lack of 
effective therapeutic options, and prognosis remains poor 
with a median survival of approximately 12 months [6, 7]. 
There is an urgent need to better understand MPM biology, 
to test new markers for diagnosis and prognosis, and to 
identify tumor targets for novel therapeutic strategies. 
In the last decade, we established that CD157 
(BST1), a glycosylphosphatidylinositol (GPI)-anchored 
member of the NADase/ADP-ribosyl cyclase gene family 
[8], regulates cytoskeleton reorganization and diapedesis 
in human leukocytes by a non-enzymatic receptor activity 
[9]. We also demonstrated that CD157 is expressed in 
epithelial ovarian cancer where it contributes to tumor 
progression by promoting mesenchymal differentiation 
[10] and is an independent prognostic factor of reduced 
survival [11]. Ovarian surface epithelial cells and 
mesothelial cells share embryonic origin, and have 
common biological and morphological properties. 
Moreover, their malignant counterparts show similar 
mechanisms of dissemination. The evident parallels 
between ovarian and mesothelial cancer prompted 
speculation that CD157 might also be involved in MPM. 
This study was undertaken to investigate the clinical 
relevance and biological role of CD157 in MPM.
RESULTS
CD157 expression and distribution in MPM
To explore the feasibility of studying CD157 in 
MPM, we first examined CD157 expression in nine human 
MPM cell lines. CD157 mRNA and protein expression 
was detected in two out of five epithelioid MPM cell lines 
(CD157-positive: MMP and MPP89; CD157-negative: 
REN, IST-MES-1 and IST-MES-2) and in one out of three 
biphasic MPM cell lines (CD157-positive: CG98; CD157-
negative: MSTO and CE96). OC99 sarcomatoid MPM 
cell line was negative (Fig. 1A, B). On the same panel of 
MPM cell lines we investigated the expression of CD38, 
the other member of the NADase/ADP-ribosyl cyclase 
gene family. CD38 was detected in the IST-MES-1 and 
IST-MES-2 epithelioid MPM and in CE96 biphasic MPM 
cell lines (Supplementary Fig. S1).
We proceeded with a retrospective analysis of 
CD157 expression in 81 MPM surgical specimens 
(37 epithelioid and 44 biphasic; no specimens from 
sarcomatoid patients as surgery was not an option). Patient 
characteristics are reported in Supplementary Table S1. 
By immunohistochemistry, CD157 was detected in 85.2% 
of the specimens, evenly distributed among epithelioid 
(86.5%) and biphasic (84%) tumors. The CD157 H-score 
varied considerably among samples, ranging from 10 
to 230 (median = 50), with no statistically significant 
difference between epithelioid and biphasic histotypes (p 
= 0.6654, Mann-Whitney U test). With the overall median 
H-score as cut-off, tumor specimens were divided into 
those with CD157 H-score ≤50 or H-score >50 (Fig. 1C). 
Discrete subcellular patterns of CD157 localization 
were observed: cytoplasmic staining with diffuse granular 
or perinuclear spots was prevalent in 52.2% of surgical 
MPM tissues (Fig. 1D, panels b-d) while staining was 
mainly in the plasma membrane with apical localization in 
47.8% of the specimens (Fig. 1D, panels e-h). Subcellular 
localization was independent of CD157 H-score and 
histotype (p = 0.116 and p = 0.821, respectively, Fisher’s 
exact test). In biphasic MPM, both epithelioid and 
sarcomatoid components expressed CD157. Homogeneous 
CD157 staining was also detected in mesothelial cells 
adjacent to the tumor (Fig. 1D, panel a) and, as expected 
[9], in the endothelial lining of blood vessels (Fig. 1D, 
panel f). 
CD157 expression was also evaluated in 20 
consecutive thoracoscopic biopsies from patients with 
sarcomatoid MPM (Supplementary Table S2). Nine out of 
twenty (45%) specimens expressed CD157. The H-score 
ranged from 10 to 50, a statistically significant difference 
in distribution compared to the CD157 H-score observed 
in epithelioid and biphasic MPM (p < 0.001; Fig. 1C). 
CD157 expression correlates with clinical 
variables and survival in MPM
 CD157 expression did not associate with sex, 
patient age at surgery, histology, asbestos history, disease 
stage or patient outcome when the 81 surgical MPM 
specimens were sorted according to the median CD157 
H-score (Supplementary Table S3). The prognostic 
significance of the CD157 H-score and other clinical 
variables was estimated by univariate analysis for 
survival: tumor histology and advanced stage of disease 
correlated with a statistically significant increased risk of 
death (Table 1A). 
Because epithelioid and biphasic MPM have 
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different prognoses, the correlation between survival and 
CD157 H-score or other clinical variables was analysed 
separately in the two histotypes. In epithelioid MPM, 
univariate analysis indicated that only early tumor stages 
were associated with longer survival times (early versus 
late stages, HR = 2.260, 95% CI = 1.061 to 4.814, p = 
0.035); there was no correlation between survival and 
CD157 H-score (data not shown). In biphasic MPM, in 
addition to advanced stage of disease and pleurectomy/
decortication, the CD157 H-score >50 also correlated 
with poor prognosis (Table 1B). By Kaplan-Meier 
analysis, median survival was 13.067 months in patients 
with biphasic MPM and CD157 H-score >50 (95% CI = 
4.771 to 21.362); with CD157 H-score ≤50, the median 
survival was 20.433 months (95% CI = 16.546 to 24.321; 
log-rank test p = 0.037) (Fig. 1E). The multivariable Cox 
proportional hazard model applied to biphasic MPM 
confirmed that CD157 H-score was an independent 
predictor of survival (Table 1B). 
In biphasic MPM, subcellular CD157 localization 
also correlated with statistically significant differences in 
survival, with membrane localization associated with the 
worst prognosis (HR = 2.031, 95% CI = 1.022 to 4.038). 
Kaplan-Meier analysis stratified by CD157 subcellular 
localization demonstrated that median OS was 13.067 
months (95% CI = 7.509 to 18.624) for biphasic MPM 
patients with membrane CD157 and 18.633 months 
(95% CI = 13.301 to 23.966; log-rank test p = 0.039) for 
Figure 1: Expression of CD157 in MPM and correlation with patient outcome. (A) RT-PCR analysis of CD157 in MPM 
cell lines. GAPDH was used as housekeeping gene. (B) CD157 expression in MPM cell lines by flow cytometry. Cells were stained 
with the RF3 anti-CD157 mAb (unshaded peaks) or isotype-matched mAb (shaded peaks). (C) Comparison of CD157 H-score in MPM 
specimens. Tumors were sorted by histotype and plotted against the CD157 H-score. Each data point corresponds to the CD157 H-score 
of an individual tumor. Boxes indicate the range (25th-75th percentiles), whiskers indicate major and minor values; the horizontal line 
within the boxes indicates the median H-score of each group. The median H-score of 50 was used as the cut-off criterion for the epithelioid 
and biphasic MPM (dotted line). (D) Immunohistochemical staining of CD157 in MPM. (a) Expression of CD157 in peritumoral, non-
malignant mesothelial cells (magnification ×200); (b) clonal expression of CD157 in tumor cell clusters in epithelioid MPM (×100); (c) 
computerized magnification of the white square in panel b highlighting granular cytoplasmic CD157 staining; (d) granular cytoplasmic 
CD157 staining in sarcomatoid component in biphasic MPM (×200); (e) CD157 membrane staining in epithelioid MPM (×200); (f) tumor 
infiltrate in a lymph vessel. (*) indicates CD157 staining of the endothelial lining of a blood vessel (×100). (g) CD157-positive cell clusters 
in epithelioid MPM (×100); (h) Membrane localization of CD157 with (*) strong apical staining (×400). E, Kaplan-Meier analysis of 
survival in 44 patients with biphasic MPM dichotomized for CD157 expression at the median H-score (= 50).
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Table 1: Univariate and multivariate analysis of survival
A
 Univariate analysis Multivariate analysis
No. of 
cases
Median 
survival 
(months)
HR (95% CI) p HR (95% CI) p
Sex 0.917 (0.551-1.527) 0.74
0.969 (0.535-
1.755) 0.917
Male 60 17.067
Female 21 21.567
Age at surgery, 
years
1.480 (0.931-
2.353) 0.095
1.322 (0.821-
2.130) 0.25
<55 33 20.767
≥55 48 16.833
Asbestose exposure 1.064 (0.680-1.664) 0.785
1.046 (0.640-
1.710) 0.858
No 40 20.433
Yes 41 16.433
Histological type 1.724 (1.074-2.768) 0.022
1.536 (0.924-
2.556) 0.098
Epithelioid 37 19.6
Biphasic 44 16.533
Disease stage, 
IMIG
2.144 (1.327-
3.466) 0.001
2.073 (1.148-
3.744) 0.016
I/II/III 52 22.167
IV 29 11.967
Surgical treatment 1.009(0.618-1.648) 0.972
0.963 (0.547-
1.697) 0.897
EPP 56 16.533
P/D 25 18.633
Resection margin 
status
1.340 (0.855-
2.100) 0.199
1.122 (0.584-
2.158) 0.729
radical (R0) 37 22.467
non radical (R1) 44 15.733
Post-surgical 
therapy
1.217 (0.779-
1.900) 0.388
1.416 (0.835-
2.402) 0.196
No 40 18.167
Yes 41 16.533
CD157-H-score 0.966 (0.619-1.509) 0.881
1.054 (0.628-
1.768) 0.842
≤50 41 18.167
>50 40 16.533
B
Biphasic MPM=44  Univariate analysis Multivariate analysis
 No. of cases
Median 
survival 
(months)
HR (95% CI) p HR (95% CI) p
Sex 1.381 (0.661-2.884) 0.388
1.304 (0.582-
2.918) 0.519
Male 34 17.067
Female 10 15.267
Age at surgery, 
years
1.120 (0.601-
2.087) 0.722
0.735 (0.318-
1.699) 0.471
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patients with cytoplasmic CD157 (Supplementary Fig. 
S2A). Biphasic MPM patients with CD157 H-score >50 
and membrane CD157 had the worst prognosis: median 
OS was 10.9 months (95% CI = 9.102 to 12.698) versus 
16.533 months for patients with biphasic MPM, CD157 
H-score >50 and cytoplasmic CD157 (95% CI = 13.874 
to 19.193; log-rank test p = 0.044) (Supplementary Fig. 
S2B). 
Linking CD157 expression to mesothelioma cell 
growth and tumorigenicity 
The finding that CD157 expression correlated with 
poor prognosis in patients with biphasic MPM triggered 
an investigation into the influence of CD157 on tumor 
cell behavior in vitro. Based on the analysis of CD157 
expression in MPM cell lines reported above, we selected 
CD157-positive (biphasic CG98 and epithelioid MPP89) 
cell lines for gene knockdown to investigate the effects 
of loss of CD157 expression. In brief, from the parental 
CD157-positive cell lines, we generated stable CD157 
knockdown versions (with CD157-specific shRNA) and 
controls that conserved endogenous expression of CD157 
(with control shRNA). In a complementary approach, we 
selected CD157-negative (biphasic MSTO and epithelioid 
REN) cell lines and transfected them to assess the effects 
of gain of CD157 expression. From the parental CD157-
negative cell lines, we generated CD157-positive versions 
by stable CD157 cDNA transfection (and empty vector 
control cell lines that remained constitutively CD157-
negative). The CD157 status of the eight genetically 
engineered cell lines was assessed by RT-PCR, western 
blot and flow cytometry (Fig. 2A, B). Endogenous and 
exogenous expression levels of CD157 were comparable 
whereas CD157 shRNA-mediated knockdown effectively 
abolished expression of CD157 (Fig. 2A, B). 
We first evaluated the effects induced by loss or 
gain of CD157 expression on cell morphology, growth 
and tumorigenicity. By light microscopy, we observed 
that CD157 expression affected cell morphology in 
biphasic, but not epithelioid, cell lines. Morphology 
was more spindle-like with reduced cell spreading in the 
biphasic CD157-positive (endogenous CG98 or exogenous 
MSTO) cell lines compared to their CD157-negative 
(knockdown CG98 or constitutive MSTO) counterparts 
<55 17 18.000
≥55 27 16.533
Asbestose exposure 1.128 (0.617-2.063) 0.695
1.142 (0.562-
2.322) 0.713
No 20 18.167
Yes 24 15.733
Disease stage, 
IMIG
1.990 (1.050-
3.743) 0.03
1.500 (0.494-
4.553) 0.474
II/III 27 20.767
IV 17 12.900
Surgical treatment 2.219 (1.081-4.556) 0.026
1.335 (0.474-
3.760) 0.584
EPP 31 17.067
P/D 13 15.267
Resection margin 
status
1.609 (0.877-
2.953) 0.121
1.383 (0.365-
5.235) 0.633
radical (R0) 21 20.433
non radical (R1) 23 15.267
Post-surgical 
therapy
0.894 (0.488-
1.639) 0.717
0.932 (0.380-
2.284) 0.877
No 19 18.167
Yes 25 16.533
CD157-H-score 1.933 (1.029-3.631) 0.037
2.433 (1.120-
5.284) 0.025
≤50 21 20.433
>50 23 13.067
CI = confidence interval; HR= hazard ratio
p values were calculated using two-sided log-rank test for univariate analysis and two-sided Wald 
test for multivariate analysis.
EPP, extrapleural pneumonectomy; P/D, pleurectomy/decortication 
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Figure 2: CD157 influences MPM cell morphology and growth. (A) CG98 and MPP89 cells were stably transduced with 
a CD157-specific shRNA (sh-CD157) or a scrambled shRNA (sh-control). (B) MSTO and REN cells were stably transfected with the 
pcDNA3.1 expression vector containing full-length CD157 cDNA (pcDNA-CD157), or with the empty vector (pcDNA-control). CD157 
mRNA and protein expression were analysed by RT-PCR, western blot and flow cytometry. GAPDH, β-actin and an isotype matched mAb 
(gray shaded peaks) were used as controls, respectively. (C) Light microscopy images showing the morphological features of cells with 
or without CD157 stained with crystal violet and reproduced in black and white (magnification ×10). (D) Western blot for fibronectin. (E) 
MTT viability assay of MPM cells. Results represent the mean ± SEM of three independent experiments performed in quadruplicate. (F) 
Colony formation assay of MPM cells. Colonies were stained with crystal violet and reproduced in black and white. (G) Clonogenic assay 
in soft agar. Columns represent the average number of colonies/10 fields from three independent experiments ± SEM. ****p < 0.0001, ***p 
< 0.001,**p < 0.01,*p < 0.05, ns = not significant, two-tailed unpaired t test.
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(Fig. 2C). This spindle-shaped morphology was associated 
with abundant expression of fibronectin, especially in 
CD157-positive CG98 cells. However, in the CG98 
CD157 knockdown cells, there was a striking reduction 
in fibronectin expression (Fig. 2D). Contrasting with the 
impact of CD157 in biphasic MPM cell lines, epithelioid 
cell line morphology and fibronectin expression remained 
essentially unchanged by modulation of CD157 (Fig. 2C, 
D). 
In cell proliferation assays, CD157 expression 
affected the biphasic, but not epithelioid, MPM cell lines: 
loss of CD157 significantly reduced the growth of CG98 
but not of MPP89 cells compared to their CD157-positive 
controls, whereas forced expression of CD157 enhanced 
the growth of MSTO but not those of REN cells (Fig. 2E). 
As a further marker of cell growth, plating efficiency was 
examined: CD157 knockdown reduced the number and 
size of colonies in CG98 cells whereas CD157 expression 
significantly increased plating efficiency in MSTO cells. 
MPP89 and REN cells with or without CD157 showed 
similar number of colonies of comparable size (Fig. 2F). 
By soft agar assay, a conventional in vitro measure of 
cell tumorigenicity, exogenous expression of CD157 led 
to a significant increase in number of colonies in MSTO 
cells, but not in REN cells (Fig. 2G). CG98 and MPP89 
cells were unable to grow in the absence of anchorage 
(regardless of the expression of CD157), hampering their 
use in soft agar assays. 
Linking the expression of CD157 to MPM cell 
migration and invasiveness
The propensity of MPM to spread by invasive 
growth along the pleura is a major determinant of tumor 
outcome. We investigated the relevance of CD157 
expression in cell motility and invasiveness using three 
conventional assays of tumor aggressiveness. First, in 
wound healing scratch assays, CD157 knockdown in 
CG98 cells led to a marked reduction (~25%) in wound 
closure at 24 hours compared to CD157-positive CG98 
cells. Conversely, gain of CD157 in MSTO cells increased 
motility. Gain or loss of CD157 did not affect motility in 
the epithelioid MPP89 and REN cells (Fig. 3A). Second, 
by directional migration assays (towards 10% FBS used 
as the chemoattractant) loss or gain of CD157 expression 
altered migration in CG98 and MSTO biphasic MPM 
but not in MPP89 and REN epithelioid MPM (Fig. 
3B). Third, we assessed the effect of CD157 on MPM 
cell invasiveness by Matrigel invasion assays. CD157 
knockdown in biphasic CG98 decreased cell invasion 
compared to the CD157-positive counterpart. MPP89 cells 
were poorly invasive independently of CD157 expression. 
Instead, gain of CD157 in biphasic MSTO and epithelioid 
REN cells markedly increased their invasive potential with 
respect to their CD157-negative controls (Fig. 3C). 
CD157 modulates the activation of mTOR
The PI3K/Akt/mTOR pathway plays a key role in 
the progression of a number of solid tumors, including 
mesothelioma (12-15). We examined the activation of 
mTOR and its downstream effector p70 ribosomal S6 
kinase1 (p70S6K) in CD157-positive and negative MPM 
cells cultured in standard conditions. By western blot, 
mTOR phosphorylation was evident in all the MPM cell 
lines analysed; however, phospho-mTOR (p-mTOR) and 
phospho-p70S6K (p-p70S6K) were more elevated in 
CG98 and MSTO biphasic cell lines expressing CD157 
(endogenous or exogenous) than in their CD157-negative 
Figure 3: CD157 increases MPM cell motility and 
invasiveness. (A) Wound-healing assay to assess CD157 
and cell motility as quantified by percent wound closure over 
24 hours (scale bar: 200 µM). (B) Transwell® assay to assess 
CD157 on cell migration toward 10% FBS. (C) Matrigel assay 
to assess CD157 on cell invasion. Migrated or invading cells 
were stained and counted in ten microscopic fields at ×100 
magnification. Results represent the mean ± SEM of three 
independent experiments. ****p < 0.0001, ***p < 0.001, **p < 
0.01, *p < 0.05, ns = not significant, two-tailed unpaired t test.
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counterparts. Gain or loss of CD157 expression in MPP89 
and REN epithelioid cell lines did not significantly perturb 
the phosphorylation status of mTOR and p70S6K (Fig. 
4A). 
Following this result, linking CD157 expression 
in biphasic MPM lines with increased mTOR 
phosphorylation in vitro, we assessed staining and 
calculated the H-score for p-mTOR and p-p70S6K in the 
same MPM surgical specimens previously used to detect 
CD157 expression. In biphasic MPM tissue samples, there 
was a positive linear correlation between the H-score of 
CD157 and both those of p-mTOR and of p-p70S6K (Fig. 
4B, left panels). The analysis of distribution of p-mTOR 
and p-p70S6K H-scores demonstrated that biphasic MPM 
with CD157 H-score >50 had significantly higher median 
H-score of p-mTOR and p-p70S6K than those with CD157 
H-score ≤50 (Fig. 4B, right panels). In epithelioid MPM 
no correlation was found between CD157 and p-mTOR 
H-scores (r = 0.2826, p = 0.0902 Spearman’s correlation 
test) or p-p70S6K H-scores (r = 0.1279, p = 0.4506, 
Spearman’s correlation) (n = 37, data not shown). 
CD157 modulates responsiveness to chemotherapy 
through mTOR activation 
The activation of the mTOR/p70S6K axis is also 
implicated in resistance to chemotherapy, including 
platinum compounds widely used to treat MPM [16, 17]. 
We used our CD157-positive and negative MPM cell 
line models to assess the cytotoxic effect of increasing 
concentrations of cisplatin (CDDP) or carboplatin (CPT), 
and to establish their cytotoxic potency (IC50). Biphasic 
cell lines expressing CD157 were significantly more 
resistant to both CDDP and CPT than their CD157-
negative counterparts. In CG98, although CD157-positive 
and negative cells had similar IC50, the CD157-positive 
cells showed greater resistance to treatment for 48 hours 
with low-dose (1.25-2.5 µM) CDDP. Likewise, CD157-
positive CG98 was more resistant to CPT treatment 
compared to CG98 CD157-negative cells (Fig. 5A, left 
panels). MSTO CD157-positive cells were significantly 
more resistant to both CDDP and CPT treatment, and 
showed a markedly increased IC50 value compared to 
MSTO CD157-negative cells (Fig. 5A, right panels). In 
MPP89 and REN epithelioid cell lines, gain or loss of 
CD157 did not influence their sensitivity to CDDP or CPT 
(Supplementary Fig. S3). 
To investigate if the link between CD157 expression 
and platinum sensitivity in biphasic MPM was associated 
with mTOR activation, CD157-positive and -negative 
CG98 and MSTO cells were exposed to 10 nM rapamycin 
(mTOR inhibitor [18]) for 8 hours before treating with 
CDDP or CPT at concentration close to each IC50 values. 
Rapamycin alone moderately reduced viability in all 
cell lines. Exposure to rapamycin then to CDDP or CPT 
enhanced cytotoxicity compared to treatment with either 
CDDP or CPT alone. Notably, when pretreated with 
rapamycin, biphasic CG98 and MSTO CD157-positive 
cell lines showed significant recovery of sensitivity to 
CDDP and CPT (Fig. 5B). 
Finally, we explored the relationship between 
CD157 expression and response to platinum-based 
chemotherapy in vivo, defined in terms of survival 
advantage. The influence of CD157 expression on 
survival was evaluated in 41 patients in our cohort, treated 
postoperatively with platinum-based chemotherapy (22/44 
Figure 4: Linking CD157 expression with mTOR 
activation in biphasic MPM. (A) Western blot of 
phosphorylated mTOR and p70S6K proteins in CD157-
positive and negative cells grown in medium with 10% FBS 
for 24 hours. β-actin was used as loading control. Results of 
densitometric analysis are expressed as fold changes compared 
to each corresponding control and are the means ± SD of three 
independent experiments. (B) CD157 H-score correlates with the 
p-mTOR and p-p70S6K H-scorers in biphasic MPM specimens 
(3 missing due to lack of material, left panels). Distribution of 
p-mTOR and p-p70S6K H-scores (right panels) confirmed that 
tumors with CD157 H-score >50 had higher median p-mTOR 
and p70S6K H-score than tumor with CD157 H-score ≤50 (p = 
0.0085 and p = 0.0125, respectively). Boxes indicate the range 
(25th-75th percentiles), whiskers indicate major and minor values, 
and the horizontal line within the boxes indicates the median 
H-score of each group. 
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patients with biphasic and 19/37 with epithelioid MPM). 
By univariate analysis, chemotherapy did not predict 
survival benefit for patients with either biphasic (log-rank 
test p = 0.419) or epithelioid (log-rank test p = 0.114) 
MPM. However, when chemotherapy-treated or untreated 
biphasic MPM patients were grouped according to CD157 
H-score, the group with chemotherapy and CD157 H-score 
>50 showed a clear trend towards shorter survival than 
the group with chemotherapy and CD157 H-score ≤50, 
although the difference was not statistically significant 
(log-rank test p = 0.062) (Fig. 5C). In contrast, the 40 
patients who did not receive postoperative chemotherapy 
showed no correlation between CD157 H-score and 
survival (log-rank test p = 0.178, data not shown). No 
prognostic correlation was observed in patients with 
epithelioid MPM among chemotherapy response, CD157 
Figure 5: CD157 modulates responsiveness to chemotherapy in biphasic MPM. (A) Drug sensitivity assays showing the 
viability of CD157-positive and negative cells treated with increasing concentrations of CDDP (top panels) or CPT (bottom panels) for 
48 hours. Absorbance was read and each data was normalized to the respective untreated control and plotted. Results represent the mean 
± SEM of at least three experiments performed in quadruplicate. Each IC50 is indicated. (B) Effect of rapamycin on CG98 and MSTO 
cells sensitivity to CDDP and CTP. Cells were exposed to 10 nM rapamycin for 8 hours before treatment with CDDP, CPT or vehicle for 
48 hours. Data are the mean ± SD of one representative experiment of three performed in quadruplicate. ****p < 0.0001, ***p < 0.001, 
**p < 0.01, *p < 0.05, ns = not significant. (C) Patients with biphasic MPM who received platinum-based chemotherapy were subdivided 
according to median CD157 H-score. Kaplan-Meier analysis shows that patients with CD157 H-score >50 (solid line) had a shorter (albeit 
not statistically significant, log-rank test p = 0.062) survival than patients with H-score ≤50 (dashed line). 
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H-score and survival (data not shown). These data suggest 
that CD157 could be a promising candidate as a predictive 
marker of response to platinum-based therapy in biphasic 
MPM patients. 
DISCUSSION
The increasing worldwide incidence of MPM 
poses many urgent challenges. Among these, a better 
understanding of the molecular mechanisms driving MPM 
progression is a priority as it will ultimately translate into 
better diagnosis and treatment. 
In this paper, we report that CD157/BST1 is 
expressed in the most common types of MPM, and in 
several MPM cell lines. High CD157 expression was 
found consistently associated with exacerbated tumor 
aggressiveness in the biphasic histotype both in vitro and 
in vivo. Indeed, i) in the CD157-negative/CD157-positive 
biphasic MPM cell line models, CD157 expression 
correlated with enhanced cell growth, migration, invasion 
and resistance to platinum-based chemotherapy; ii) in 
patients with biphasic MPM, high CD157 H-scores 
correlated with shorter survival with respect to patients 
with low CD157 H-score. The independent prognostic 
value of CD157 in biphasic MPM was further confirmed 
by multivariate survival analysis. 
Our preceding studies have clearly demonstrated 
that CD157 can confer malignant and invasive traits to 
epithelial ovarian cancer by promoting mesenchymal 
differentiation [10]. More recent studies have shown that 
CD157 regulates cell adhesion to the extracellular matrix 
(ECM) [19] and binds selected ECM proteins, including 
fibronectin [20] which has a central role in mesenchymal 
differentiation [21]. This data indicates that CD157 is 
involved in EMT and suggests that the CD157/ECM 
interplay in the tumor microenvironment could be critical 
in determining the aggressiveness of CD157-positive 
tumors by facilitating the EMT differentiation program 
ongoing in biphasic MPM [5, 22]. This is supported by 
the observation that the expression of CD157 emphasized 
some distinctive mesenchymal properties of biphasic 
CG98 and MSTO MPM cell lines, such as spindle-
shape morphology, motility, invasiveness and resistance 
to chemotherapy [23]. Apparently, CD157 expression 
did not impinge upon MPP89 and REN epithelioid cell 
morphology, motility and drug resistance. However, 
when cultured in the presence of a surrogate ECM 
(such as Matrigel) that generates a more permissive 
environment, CD157-positive epithelioid REN cells 
showed enhanced invasiveness with respect to CD157-
negative cells. This suggests that CD157 relies on specific 
microenvironmental cues to accomplish its function. In 
MPM, each histotype produces different growth factors 
and ECM proteins, influencing the composition of the 
tumor microenvironment and the proclivity of each 
tumor to spread and disseminate [22, 24]. It is tempting 
to envision that in vivo the local auto/paracrine secretion 
of different ECM components affects the surrounding 
tumor microenvironment thereby determining the pro-
tumorigenic functions of CD157 in patients with MPM. 
However, whether the CD157-driven pro-tumorigenic 
effect is exclusively due to its interaction with the ECM or 
whether it is dependent on other mechanisms implemented 
in the tumor niche (such as, CD157’s involvement in the 
cancer cells/stroma interaction) remains to be established. 
The acquisition of EMT and gain of stem-like 
features are strictly interconnected and contribute to tumor 
growth and dissemination. Since CD157 is a marker of 
stem cell both in human [25] and mouse [26, 27], the 
hypothesis that CD157 serves as a point of convergence 
in conferring mesenchymal and stem-like differentiation 
to mesothelioma cells is intriguing and deserve further 
investigation.
In MPM tumor tissues, CD157 expression was 
heterogeneous both in terms of H-score and subcellular 
localization, a feature common to many other markers in 
solid tumors [28, 29]. At present, we do not know how 
high versus low and membrane versus cytoplasm patterns 
of CD157 expression affect its role in MPM. However, 
patients with high and membrane-localized CD157 
expression had a worse prognosis than patients with 
cytoplasmic localization, further corroborating the notion 
that the interaction with currently unidentified components 
in the tumor microenvironment is critical for CD157 to 
exert its functions. 
Increasing evidence indicates that the Akt/mTOR 
pathway is frequently activated in MPM [30] and plays a 
key role in tumor aggressiveness and chemoresistance [15, 
31, 32]. However, in MPM, the molecular mechanism(s) 
leading to activation of mTOR and its interaction with 
other biomarkers are largely unknown. The interplay 
between CD157 and the mTOR pathway recently 
demonstrated in mice [33] and the role of CD157 in 
MPM aggressiveness prompted us to investigate this 
pathway. Several lines of evidence suggest that CD157 
exerts its pro-tumorigenic effects through the activation 
of mTOR. First, consistently greater phosphorylation of 
mTOR and its downstream effector p70S6K was found in 
CD157-positive versus CD157-negative biphasic (but not 
epithelioid) MPM cell lines. Second, a positive correlation 
emerged between the expression of CD157 and the extent 
of mTOR and p70S6K phosphorylation in primary tumors 
from patients with biphasic MPM, thus strengthening the 
existence of a relationship between CD157 expression and 
activation of mTOR in vivo. 
Activation of mTOR has an established role in the 
generation of chemotherapy resistance in several tumors 
[34, 35]. Consistently, both CD157-positive CG98 and 
MSTO biphasic cell lines showed reduced sensitivity 
to cisplatin and carboplatin treatment compared to the 
corresponding CD157-negative cells. Although further 
studies are required before drawing definitive conclusions, 
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clinical data indicated that patients with biphasic MPM 
and high CD157 H-score receiving platinum-based 
therapy had shorter survival than patients with low CD157 
H-score. Finally, treatment with rapamycin (a prototypic 
mTOR inhibitor) [36] restored sensitivity in cisplatin- 
and carboplatin-resistant CD157-positive CG98 and 
MSTO cells, confirming that CD157-mediated platinum 
resistance at least partly relies on the activation of mTOR. 
Overall, our in vitro and in vivo studies point to CD157 as 
a promising marker of efficacy for treatment with platinum 
compounds in patients with biphasic MPM. So far, the 
availability of dependable predictive markers of response 
to therapy is poor, among these CD26 is emerging as a 
promising candidate since its expression was found 
associated with better response to chemotherapy [37]. As 
mesothelioma represents a great challenge to clinicians 
and researchers due to its poor prognosis and marked 
resistance to current therapies [4, 38], finding markers that 
will identify group of patients most likely to benefit from a 
specific chemotherapy regimen is an important goal. 
Collectively, our data highlight a pivotal role of 
CD157 in multiple aspects of MPM progression and 
suggest that CD157 has clinical potential as a marker 
for stratifying patients with biphasic MPM into different 
prognostic groups. Moreover, CD157 may identify 
patients with highly aggressive MPM which might benefit 
from a particular chemotherapeutic approach that may 
include mTOR inhibitors.
MATERIALS AND METHODS
Antibodies and reagents
RF3 anti-CD157 monoclonal antibody (mAb) (IgG1, 
MBL International) and anti-fibronectin (Sigma-Aldrich) 
were used. Horseradish peroxidase (HRP)-conjugated 
goat-anti-rabbit, HRP-goat-anti-mouse polyclonal IgG 
and HRP-anti-β-actin (sc-1615) antibodies were from 
Santa Cruz Biotechnologies. Anti-mTOR (L24D4, #4517), 
anti-phospho-mTOR (Ser2448/49F9, #2976), anti-p70S6K 
(49D7, #2708) and anti-phospho-p70S6K (Thr389/1A5, 
#9206) antibodies were from Cell Signalling Technology. 
FITC-labeled F(ab′)2 fragments from goat antibodies 
to mouse IgG were from Jackson ImmunoResearch. 
Original stock solutions of cisplatin (cis-diammine-
dichloroplatinum; Pfizer) (1 mg/ml) and carboplatin 
(Platinum, diammine[1,1-cyclobutanedicarboxylato(2-
)-O,O’], Teva Pharma Italia) (10 mg/ml) were stored at 
-20°C and freshly dissolved in culture medium at time of 
use.
Patients and tissue samples
Tissue sections were retrospectively obtained from 
81 consecutive specimens (37 epithelioid; 44 biphasic) 
from patients operated for MPM between 1998 and 2005 
at the San Giovanni Hospital (Torino, Italy) [39, 40]. 
Because of its surgical origin, this cohort did not reflect the 
expected prevalence of the epithelioid histological type. 
Patient characteristics are reported in Suppl. Table S1. 
Tumor stage was determined according to the International 
Mesothelioma Interest Group (IMIG) staging system. 
Occupational exposure to asbestos was documented in 
41 patients. Median overall survival (OS) was 18 months. 
We obtained 20 consecutive thoracoscopic biopsies of 
sarcomatoid MPM diagnosed between 2004 and 2010 at 
the San Luigi Hospital (Orbassano, Italy). A pathologist 
blinded to the purpose of the study anonymized samples 
and clinical data. The study was approved by the local 
Institutional Review Board.
Immunohistochemistry
Five μm deparaffinized sections from formalin-fixed 
MPM samples were analysed using RF3 (anti-CD157), 
49F9 (anti-phospho-mTOR) and 1A5 (anti-phospho-
p70S6K) mAbs, as previously described by our groups 
[11, 41]. All samples were evaluated using a semi-
quantitative histological score (H-score) which took into 
account both the percentage of positive tumor cells within 
the whole section and the intensity of immunostaining. 
The H-score was calculated by summing percentage of 
cells stained at each intensity level (0–100) multiplied by 
the weighted intensity (0, none; 1, weak; 2, moderate; 3, 
intense), generating for each tumor a semi-quantitative 
score ranging from 0 to 300. 
Cell lines, transfections and transductions
The human MPM cell lines MSTO-211H 
(designated MSTO) [42], MPP89, IST-MES-1 and IST-
MES-2 [43] were purchased from Interlab Cell Line 
Collection (Genova, Italy), REN [44] was kindly provided 
by L. Moro (University of Novara, Italy) who received 
the cells from S. Albelda (University of Pennsylvania, 
Philadelphia, USA); CE96, OC99, CG98 and MMP cell 
lines were obtained from the mesothelioma bio bank, 
Pathology Unit, City Hospital of Alessandria (Italy) [45]. 
Cells were cultured as recommended by each provider. 
All cell lines were thawed from early-passage frozen 
stocks and were passaged less than twenty times prior to 
use. Cell lines were regularly examined for morphology; 
Mycoplasma contamination was excluded using a PCR-
based assay. CD157 knockdown was obtained by lentiviral 
delivery of pLV-puro plasmid (Biosettia) encoding a short 
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hairpin RNA (shRNA) targeting the 3’ UTR of BST1 
mRNA, as described (10). Scrambled shRNA controls 
were always included. CD157 expression was obtained 
by transfection with the pcDNA3.1 eukaryotic expression 
vector (Invitrogen) containing full-length CD157 cDNA 
(GenBank NM_004334). Control was empty vector, as 
described [11]. 
RNA extraction and reverse transcriptase-PCR
Total RNA (2 μg) extracted from 70-80% confluent 
cell cultures using TRI Reagent® (Sigma Aldrich) 
was reverse-transcribed with the M-MLV Reverse 
Transcriptase (Thermo Fisher Scientific) and Oligo-
dT primers. cDNA was amplified using KAPA2G 
Fast HotStart DNA Polymerase (Kapa Biosystems, 
Wilmington, MA, USA). Each cycle consisted of 
denaturation at 95°C for 10 s, annealing for 10 s and 
extension at 72°C for 1 s. The primers used were as follow: 
CD157, 5′-CCAAAGTTCCCCGATGGCGGCC-3′ 
(forward) and 5′-GGTTAGAGCAACACAGTTTCC-3′ 
(reverse), GAPDH, 5′-GAGTCAACGGATTTGGTCGT-3′ 
(forward) and 5′-TTGATTTTGGAGGGATCTCG-3′ 
(reverse). PCR products were analyzed by electrophoresis 
on 1% agarose gel stained with Midori-green (Nippon 
Genetics Europe, Dueren Germany).
Flow cytometry 
Engineered MPM cells were incubated with RF3 
mAb (5 µg/ml) for 30 min at 4°C followed by F(ab′)2-
GαMIg-FITC (5 µg/ml) for 30 min at 4°C. Background 
mAb binding was estimated by staining an identical cell 
population with an isotype-matched irrelevant control 
mAb. Fluorescence was analyzed using a FACSCanto 
flow cytometer (BD Biosciences). Ten thousand cells were 
considered for each analysis.
Cells proliferation assay
Cells (3-5×103/well) were seeded in 96-well plates 
in culture medium supplemented with 10% FBS for the 
indicated time. At the end of the experiment, MTT (5 
mg/ml) was added to each well for 1 h at 37°C, then, the 
reaction was stopped by adding DMSO (Sigma-Aldrich) 
and cell proliferation evaluated. Absorbance was read 
at 570 nm with reference at 680 nm, using a microplate 
reader (Bio Rad). At each indicated time, fold increase 
of the optical density (OD) compared to time zero was 
plotted for each cell line and compared in CD157-positive 
versus CD157-negative cells at each time points using a 
Student’s t test.
Colony forming assay
Plating efficiency, a measurement of the number 
of colonies originating from single cells, was used to 
determine the clonogenic ability of MPM cells. Briefly, 
cells (500/well) were seeded in 6-well plates and 
maintained in culture medium with 10% FBS for 2 weeks, 
then washed, fixed with methanol for 30 min, stained with 
0.2% crystal violet (Sigma-Aldrich) and counted using an 
IX70 inverted microscope equipped with a UC30 camera 
and the CellF analysis software (Olympus Biosystems).
Soft agar assay
Cells (3×103) were suspended in 1.5 ml of 0.45% 
low melting agar-containing RPMI with 10% FBS and 
then overlaid on a 0.9% agar base layer in 6-well culture 
plates. One ml of RPMI with 10% FBS was added on 
the top. After 2 weeks incubation at 37°C and 5% CO2, 
colonies were stained with 0.2% crystal violet, visualized 
under an inverted microscope and those with >50 cells 
were counted as described above. 
Wound healing assay
Cells were seeded in 24-well plates until confluence 
and a scratch was then made across the monolayer. 
Migration efficiency, expressed in term of percentage of 
wound closure, was calculated by measuring 20 randomly 
chosen distances across the wound at time 0 and 24 h, 
divided by the mean distance measured at time zero. 
Images of the wounded area were recorded using an 
Olympus Biosystems Microscope IX70, equipped with an 
UC30 camera and CellF software, at the indicated times. 
Chemotaxis and invasion assay
The directional migration of MPM cells was assayed 
using 24-Transwell® plates (BD Bioscence). For invasion 
assay, filters (8 µm pore size) were pre-coated with 30 
μg/cm2 of Matrigel (BD Biosciences). Cells (1x105) in 
serum-free medium were added to the top chamber and 
RPMI with 10% FBS was put in the lower compartment 
to stimulate cell migration or invasion. After 16 to 24 h, 
migrated cells on the bottom surface of the filters were 
fixed in methanol and stained with hematoxylin and eosin. 
The number of cells in 10 high-power fields (HPF, ×100) 
for each triplicate wells was counted and the average 
number was determined. 
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Western-blot assay 
Confluent MPM cells in culture were washed with 
PBS and cell extracts were prepared in RIPA buffer 
(Millipore) supplemented with 1 mM Na3VO4, 5 mM 
NaF, 50 μg/ml aprotinin and leupeptin Sigma-Aldrich). 
Equal amounts of proteins were separated by SDS-
PAGE, transferred to polyvinylidene difluoride (PVDF) 
membrane, and immunoblotted with the indicated 
antibodies. Images were captured with a ChemiDoc™ 
XRS+ System and densitometry analysis was performed 
with Image Lab™ Software (Bio Rad). 
Drug sensitivity assay
Cells were seeded in 96-wells plates in medium with 
10% FBS for 16 h before treatment, to allow attachment 
without cell-doubling. Cells were starved overnight, then 
treated with the indicated concentrations of cisplatin or 
carboplatin for 48 h. Cell viability was determined by 
MTT assay by comparing the OD value before and after 
treatment and normalizing the data to controls (untreated 
cells = 100%). IC50 was defined as the concentration 
causing 50% reduction in OD value relative to the 
untreated control, and it was determined by non-linear 
regression and a four-parameter logistic model with log-
transformed data. In selected experiments, after starvation, 
cells were treated for 8 h with 10 nM rapamycin (Cell 
Signaling Technology) alone or followed by the addition 
of cisplatin or carboplatin at the indicated concentrations. 
Cell viability was assessed at 48 h.
Statistical analysis
Results of in vitro experiments are shown as means 
± SEM, unless otherwise indicated. Comparisons among 
groups were performed with one-way ANOVA models; 
differences between two groups were analysed using 
two tailed t tests. The association between CD157 tumor 
expression and clinical data was analysed using the χ2 test 
or Fisher exact test. Overall survival (OS) was defined 
as the time interval from the date of surgery to the date 
of death for disease, or to the date of last follow-up for 
still alive patients. OS was analysed using Kaplan–Meier 
curves; differences in survival between groups of patients 
were assessed using the log-rank test. Univariate and 
multivariable survival analyses were performed for all 
available clinical-pathologic variables, including CD157 
H-score, using the Cox proportional hazards regression 
model. Covariates that were not statistically significantly 
associated with survival were not removed from the model 
(complete model). Crude and adjusted hazard ratios (HR) 
with relative 95% confidence interval (CI) are shown. 
Spearman’s test was used for correlation analysis between 
two factors. SPSS Statistics 20 and GraphPad Prism 6 
were used for all statistical analyses. All statistical tests 
were two-sided. p < 0.05 was considered statistically 
significant.
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